肿瘤浸润淋巴细胞评分改善II期黑色素瘤进展风险预测
该回顾性队列研究纳入4家英国医院2004-2017年366例前哨淋巴结阴性的II期黑色素瘤患者,评估AJCC第八版亚分期与TIL评分的进展预测能力。
要点
- 非活跃型TIL见于80%的进展肿瘤,提示高危。
- TIL评分可在各亚分期内区分高低危,辅助识别可能获益于辅助免疫治疗者。
核心结论
- AJCC第八版亚分期对II期黑色素瘤进展预测不佳,TIL评分可改善跨亚分期的风险分层。
- TIL评分有望作为低成本方法更好识别可能从辅助免疫治疗获益的患者。
研究设计与样本
- 回顾性队列研究,纳入4家英国医院2004-2017年前哨淋巴结阴性II期黑色素瘤患者366例,随访时间长。
主要发现
- TIL评分独立预测进展风险:活跃型 vs 非活跃型 OR 0.298,P=.009;缺失型 vs 非活跃型 OR 0.436,P=.049。
- 非活跃型TIL见于80%的进展肿瘤,提示高危。
- TIL评分可在各亚分期内区分高低危:IIA期伴非活跃型TIL患者5年无进展生存与IIB/IIC期伴缺失/活跃型TIL患者相似。
临床怎么用
- 在II期黑色素瘤风险分层中可考虑加入TIL评分,以弥补AJCC第八版亚分期的不足。
- 对IIA期伴非活跃型TIL者可按高危管理,对IIB/IIC期伴缺失/活跃型TIL者需避免过度治疗。
局限性
- 回顾性研究设计。
- 研究结果的外部推广性未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The American Joint Committee on Cancer eighth edition substaging might be suboptimal for predicting melanoma progression. Using it to select stage II patients for adjuvant immunotherapy risks overtreating low-risk stage IIB/IIC patients and undertreating high-risk stage IIA patients. Prognostic capability of tumor-infiltrating lymphocytes (TILs) is unclear in stage II melanoma. OBJECTIVE: To evaluate the American Joint Committee on Cancer eighth edition substaging and TIL scoring as predictors of progression in stage II melanoma. METHODS: Retrospective cohort study of 366 sentinel lymph node negative stage II melanoma patients from 4 UK hospitals (2004-2017), with long-term follow-up. RESULTS: Twenty-three percent of melanomas progressed (median 9.5-year follow-up). Among those, 41.5% were stage IIA, 41.5% IIB, and 17.1% IIC. TIL scoring independently predicted progression risk (brisk vs non-brisk: odds ratio: 0.298, P = .009; absent vs non-brisk: odds ratio: 0.436, P = .049) and progression-free survival. Nonbrisk TILs, present in 80% of progressing tumors, denoted high risk. TIL scoring split patients into high and low risk across substages: stage IIA patients with non-brisk TILs had similar 5-year progression-free survival to stage IIB/IIC patients with absent/brisk TILs. LIMITATIONS: Retrospective study design and unknown generalizability. CONCLUSION: Stage II melanoma progression is poorly predicted by the American Joint Committee on Cancer eighth edition substage. TIL scoring offers improved risk stratification across substages and could serve as a cost-effective method to better identify patients who may benefit from adjuvant immunotherapies.
引用
- Adigbli G, Reed B, Khera B, et al. Tumor-infiltrating lymphocyte scoring improves progression risk prediction in stage II melanoma: A retrospective cohort study. J Am Acad Dermatol. 2025. PMID: 40122211. doi:10.1016/j.jaad.2025.03.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。